Literature DB >> 10756060

Envelope glycoprotein determinants of increased fusogenicity in a pathogenic simian-human immunodeficiency virus (SHIV-KB9) passaged in vivo.

B Etemad-Moghadam1, Y Sun, E K Nicholson, M Fernandes, K Liou, R Gomila, J Lee, J Sodroski.   

Abstract

Changes in the envelope glycoprotein ectodomains of a nonpathogenic simian-human immunodeficiency virus (SHIV-89.6) that was serially passaged in vivo have been shown to be responsible for the increased pathogenicity of the resulting virus, SHIV-KB9 (G. B. Karlsson, et al., J. Exp. Med. 188:1159-1171, 1998). The 12 amino acid changes in the envelope glycoprotein ectodomains resulted in increased chemokine receptor-binding and syncytium-forming abilities. Here we identify the envelope glycoprotein determinants of these properties. A single amino acid change in the gp120 third variable (V3) loop was both necessary and sufficient for the observed increase in the binding of the SHIV-KB9 gp120 glycoprotein to the CCR5 chemokine receptor. The increased syncytium-forming ability of SHIV-KB9 involved, in addition to the V3 loop change, changes in the second conserved (C2) region of gp120 (residue 225) and in the gp41 ectodomain (residues 564 and 567). The C2 and gp41 ectodomain changes influenced syncytium formation in a cooperative manner. Changes in the V1/V2 gp120 variable loops exerted a negative effect on syncytium formation and chemokine receptor binding, supporting a previously described role of these changes in immune evasion. The definition of the passage-associated changes that determine the efficiency of chemokine receptor binding and membrane fusogenicity will allow evaluation of the contribution of these properties to in vivo CD4-positive lymphocyte depletion.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10756060      PMCID: PMC111962          DOI: 10.1128/jvi.74.9.4433-4440.2000

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  59 in total

1.  Atomic structure of a thermostable subdomain of HIV-1 gp41.

Authors:  K Tan; J Liu; J Wang; S Shen; M Lu
Journal:  Proc Natl Acad Sci U S A       Date:  1997-11-11       Impact factor: 11.205

2.  Core structure of gp41 from the HIV envelope glycoprotein.

Authors:  D C Chan; D Fass; J M Berger; P S Kim
Journal:  Cell       Date:  1997-04-18       Impact factor: 41.582

3.  Infection and pathogenicity of chimeric simian-human immunodeficiency viruses in macaques: determinants of high virus loads and CD4 cell killing.

Authors:  R Shibata; F Maldarelli; C Siemon; T Matano; M Parta; G Miller; T Fredrickson; M A Martin
Journal:  J Infect Dis       Date:  1997-08       Impact factor: 5.226

4.  Characterization of the pathogenic KU-SHIV model of acquired immunodeficiency syndrome in macaques.

Authors:  S V Joag; Z Li; L Foresman; D M Pinson; R Raghavan; W Zhuge; I Adany; C Wang; F Jia; D Sheffer; J Ranchalis; A Watson; O Narayan
Journal:  AIDS Res Hum Retroviruses       Date:  1997-05-20       Impact factor: 2.205

5.  Characterization of molecularly cloned simian-human immunodeficiency viruses causing rapid CD4+ lymphocyte depletion in rhesus monkeys.

Authors:  G B Karlsson; M Halloran; J Li; I W Park; R Gomila; K A Reimann; M K Axthelm; S A Iliff; N L Letvin; J Sodroski
Journal:  J Virol       Date:  1997-06       Impact factor: 5.103

6.  Selective employment of chemokine receptors as human immunodeficiency virus type 1 coreceptors determined by individual amino acids within the envelope V3 loop.

Authors:  R F Speck; K Wehrly; E J Platt; R E Atchison; I F Charo; D Kabat; B Chesebro; M A Goldsmith
Journal:  J Virol       Date:  1997-09       Impact factor: 5.103

7.  Effects of CCR5 and CD4 cell surface concentrations on infections by macrophagetropic isolates of human immunodeficiency virus type 1.

Authors:  E J Platt; K Wehrly; S E Kuhmann; B Chesebro; D Kabat
Journal:  J Virol       Date:  1998-04       Impact factor: 5.103

8.  Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody.

Authors:  P D Kwong; R Wyatt; J Robinson; R W Sweet; J Sodroski; W A Hendrickson
Journal:  Nature       Date:  1998-06-18       Impact factor: 49.962

9.  The antigenic structure of the HIV gp120 envelope glycoprotein.

Authors:  R Wyatt; P D Kwong; E Desjardins; R W Sweet; J Robinson; W A Hendrickson; J G Sodroski
Journal:  Nature       Date:  1998-06-18       Impact factor: 49.962

Review 10.  The HIV-1 envelope glycoproteins: fusogens, antigens, and immunogens.

Authors:  R Wyatt; J Sodroski
Journal:  Science       Date:  1998-06-19       Impact factor: 47.728

View more
  64 in total

1.  A biosensor assay for studying ligand-membrane receptor interactions: binding of antibodies and HIV-1 Env to chemokine receptors.

Authors:  T L Hoffman; G Canziani; L Jia; J Rucker; R W Doms
Journal:  Proc Natl Acad Sci U S A       Date:  2000-10-10       Impact factor: 11.205

2.  Membrane-fusing capacity of the human immunodeficiency virus envelope proteins determines the efficiency of CD+ T-cell depletion in macaques infected by a simian-human immunodeficiency virus.

Authors:  B Etemad-Moghadam; D Rhone; T Steenbeke; Y Sun; J Manola; R Gelman; J W Fanton; P Racz; K Tenner-Racz; M K Axthelm; N L Letvin; J Sodroski
Journal:  J Virol       Date:  2001-06       Impact factor: 5.103

3.  Increased mucosal transmission but not enhanced pathogenicity of the CCR5-tropic, simian AIDS-inducing simian/human immunodeficiency virus SHIV(SF162P3) maps to envelope gp120.

Authors:  Mayla Hsu; Janet M Harouse; Agegnehu Gettie; Clarisa Buckner; James Blanchard; Cecilia Cheng-Mayer
Journal:  J Virol       Date:  2003-01       Impact factor: 5.103

4.  Addition of a single gp120 glycan confers increased binding to dendritic cell-specific ICAM-3-grabbing nonintegrin and neutralization escape to human immunodeficiency virus type 1.

Authors:  James Lue; Mayla Hsu; David Yang; Preston Marx; Zhiwei Chen; Cecilia Cheng-Mayer
Journal:  J Virol       Date:  2002-10       Impact factor: 5.103

5.  Alternative coreceptor requirements for efficient CCR5- and CXCR4-mediated HIV-1 entry into macrophages.

Authors:  Kieran Cashin; Michael Roche; Jasminka Sterjovski; Anne Ellett; Lachlan R Gray; Anthony L Cunningham; Paul A Ramsland; Melissa J Churchill; Paul R Gorry
Journal:  J Virol       Date:  2011-08-10       Impact factor: 5.103

6.  Thymic pathogenicity of an HIV-1 envelope is associated with increased CXCR4 binding efficiency and V5-gp41-dependent activity, but not V1/V2-associated CD4 binding efficiency and viral entry.

Authors:  Eric G Meissner; Vernon M Coffield; Lishan Su
Journal:  Virology       Date:  2005-06-05       Impact factor: 3.616

7.  Changes in the V3 region of gp120 contribute to unusually broad coreceptor usage of an HIV-1 isolate from a CCR5 Delta32 heterozygote.

Authors:  Paul R Gorry; Rebecca L Dunfee; Megan E Mefford; Kevin Kunstman; Tom Morgan; John P Moore; John R Mascola; Kristin Agopian; Geoffrey H Holm; Andrew Mehle; Joann Taylor; Michael Farzan; Hui Wang; Philip Ellery; Samantha J Willey; Paul R Clapham; Steven M Wolinsky; Suzanne M Crowe; Dana Gabuzda
Journal:  Virology       Date:  2007-01-18       Impact factor: 3.616

8.  Genetic signatures of HIV-1 envelope-mediated bystander apoptosis.

Authors:  Anjali Joshi; Raphael T C Lee; Jonathan Mohl; Melina Sedano; Wei Xin Khong; Oon Tek Ng; Sebastian Maurer-Stroh; Himanshu Garg
Journal:  J Biol Chem       Date:  2013-11-21       Impact factor: 5.157

9.  Use of mutual information arrays to predict coevolving sites in the full length HIV gp120 protein for subtypes B and C.

Authors:  Bo Wei; Na Han; Hai-zhou Liu; Anthony Rayner; Simon Rayner
Journal:  Virol Sin       Date:  2011-04-07       Impact factor: 4.327

10.  Loss of a conserved N-linked glycosylation site in the simian immunodeficiency virus envelope glycoprotein V2 region enhances macrophage tropism by increasing CD4-independent cell-to-cell transmission.

Authors:  Po-Jen Yen; Alon Herschhorn; Hillel Haim; Ignacio Salas; Christopher Gu; Joseph Sodroski; Dana Gabuzda
Journal:  J Virol       Date:  2014-02-19       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.